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1. Introduction  
Pancreatic cancer is one of the most lethal forms of cancer and it is estimated that there will 
be about 44,000 new cases in US in the year 2011. With 37,600 estimated deaths in 2011, 
pancreatic cancer is the fourth leading cause of cancer related deaths in US (American Cancer 
Society, 2011). In spite of numerous efforts, the 5-year survival rate for pancreatic cancer has 
not improved much for the last few decades. The suggested reasons for low survival among 
the pancreatic cancer patients include late disease diagnosis, highly invasive and metastatic 
nature, lack of effective therapies, and acquisition of resistant characteristics (American cancer 
Society 2007; Moore, et al., 2003; NIH 2007). Only two drugs – gemcitabine (GEM) and 5-
fluorouracil (5FU) – have been shown to improve the survival of patients consistently. 5FU 
was the first drug to be approved as adjuvant therapy for pancreatic cancer (Kalser and 
Ellenberg, 1985; Moertel, et al., 1981). Since then, GEM has been used as the first line 
chemotherapeutic drug for pancreatic cancer. However, GEM treatment does not always 
provide extended survival benefits. A study found that in post-operative patients, GEM 
treatment increased the survival by merely 6 months (Shore, et al., 2003). 5FU is also widely 
used as an adjuvant and neoadjuvant chemotherapeutic agent to treat pancreatic cancers 
(Ahlgren, 1996; Blaszkowsky, 1998; Snady, et al., 2000).  
Although the cell death mechanisms induced by GEM and 5FU are well understood, their 
efficacy is limited due to the acquisition of drug-resistant characteristics by the cancer cells. 
Various molecular mechanisms have been suggested to play a role in development of 
resistance against these drugs. Upregulation of Akt (protein kinase B), NFκB, MDR (p-
glycoprotein) and hypoxia have been shown to impart resistance against GEM (Bergman, et 
al., 2002; Galmarini, et al., 2002; Garcia-Manteiga, et al., 2003; Nakano, et al., 2007; Yokoi and 
Fidler, 2004). Similarly, modulation of thymidylate synthetase (TS), dihydropyrimidine 
dehydrogenase (DPDY), MAPK, p53 and src imparts 5FU resistant characteristics to 
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pancreatic cancer cells (Eisold, et al., 2004; Kang and Saif, 2008; Zhang, et al., 2008; Zhao, et al., 
2006b). Epidermal growth factor receptor (EGFR) is a mitogenic receptor which has also 
been shown to provide cancer cells with proliferative and anti-apoptotic advantage (Arteaga, 
2001; Citri and Yarden, 2006). EGFR is found to be upregulated in pancreatic cancer patients’ 
tumors and the levels of EGFR correlate with aggressiveness and poor prognosis of the 
disease (Yamanaka, et al., 1993).  
2. Pancreatic cancer chemotherapy  
In spite of numerous efforts, the 5-year survival rate for pancreatic cancer has not improved 
much for last few decades. One reason contributing to this is the lack of chemotherapeutic 
agents which would effectively improve the survival of patients (American Cancer Society, 
2011; Moore, et al., 2003).  
2.1 Gemcitabine 
Gemcitabine (2’, 2’- difluorodeoxycytidine) is a difluoro analog of deoxycytidine and is the 
first line chemotherapeutic agent used in the treatment of pancreatic cancer cells. In 1997, a 
randomized trial found gemcitabine to have better clinical benefit response of 23.8% to 4.8% 
when compared to 5-fluorouracil. In the same study, the median survival for gemcitabine 
treated patients was 5.65 months versus 4.41 months for 5FU treated subjects. Comparative 
12-month survival was also increased in gemcitabine patients (18% to 2% for 5FU) (Burris, et 
al., 1997). Gemcitabine is used either alone or in combination with other agents in the 
treatment of pancreatic cancer. 
               
dCK: deoxycytidine kinase; dFdCMP: difluorodeoxycytidine monophosphate; dFdCDP: 
difluorodeoxycytidine diphosphate; dFdCTP: difluorodeoxycytidine triphosphate; CTP: cytidine 
triphosphate; CDP: cytidine diphosphate. 
Fig. 1. Gemcitabine mechanism of action 
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Gemcitabine mainly acts by three mechanisms as shown in figure 1. First, it forms dFdCTP 
(di-fluorodeoxycytidine triphosphate) by the action of enzyme deoxycytidine kinase (dCK). 
dFdCTP competes with cytidine triphosphate (CTP) to get incorporated into the DNA. 
Secondly, its diphosphate metabolite (dFdCDP) inhibits ribonucleotide reductase, further 
preventing the formation of triphosphate nucleotide. Thirdly, triphosphate metabolite 
(dFdCTP) inhibits DNA polymerase which is important for DNA repair (Huang, et al., 1991; 
Kang and Saif, 2008). Gemcitabine enters the cell via human equillibrative nucleotide 
transporter 1 (hENT1) (Mackey, et al., 1998). Patients with detectable expression of hENT had 
significantly longer survival than patients with low levels or absence of this protein 
(Spratlin, et al., 2004).  
2.2 5-Fluorouracil (5FU) 
5FU belongs to the antimetabolite class of chemotherapeutic drug and is structurally similar 
to the uracil molecule with an additional fluorine atom at position 5. The drug 5FU gets mis-
incorporated into DNA and RNA and also prevents nucleic acid synthesis by inhibiting the 
enzyme thymidylate synthase (TS). 5FU was the first drug to be approved as an adjuvant 
therapy for the treatment of pancreatic cancer. Combination of 5FU to radiation therapy 
increased the survival (10 months vs 6 months, no drug treatment) of pancreatic cancer 
patients with locally unresectable cancer (Kalser and Ellenberg, 1985; Moertel, et al., 1981). 
 
dUMP: deoxyuridine monophosphate; THF: tetrahydrofolate; dTMP: deoxythymidine monophosphate; 
DHF: dihydrofolic acid; DPDY: dihyropyrimidine dehydrogenase; dTTP: deoxythymidine triphosphate; 
TS: thymidylate synthetase; 5FU: 5-fluorouracil. 
Fig. 2. 5FU mechanism of action 
Degradation 
product 
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Due to structural similarity, 5FU enters the cell using the same facilitator transporter as 
uracil (Diasio and Harris, 1989; Santi, et al., 1974; Wohlhueter, et al., 1980). Once inside the cell 
(Fig. 2), it forms various metabolites. Among these metabolites, fluorodeoxyuridine 
monophosphate (FdUMP), fluorodeoxyuridine triphosphate (FdUTP) and fluorouridine 
triphosphate (FUTP) are the active metabolites which disrupt RNA synthesis and inhibit TS. 
5, 10-Methylenetetrahydrofolate (CH2THF) acts as the methyl donor for the conversion of 
dUMP to dTMP. 5FU binds to TS resulting in depletion of deoxythymidine triphosphate 
(dTTP) which further causes depletion in the levels of dATP, dCTP and dGTP. Imbalance in 
the ATP/dTTP ratio leads to disruption of DNA synthesis and repair (Diasio and Harris, 
1989; Howell, et al., 1981; JL, 1996; Santi, et al., 1974). 
3. Anticancer drug specific resistance 
3.1 Gemcitabine resistance 
Resistance to chemotherapeutic agents is observed commonly in mammalian tumors. 
Resistance can arise de novo or can be acquired after drug exposure. The vast genetic 
heterogeneity of cancer cells is considered to be the reason for the acquired resistance (Casa, 
et al., 2008). Cancer cells can acquire resistance against a drug through various mechanisms. 
It can prevent a drug’s entry into the cell or increase its exit from the cell. Once the drug is 
inside the cell, it can be degraded into inactive metabolites by over-expression of the 
catabolic enzyme or by inhibiting the activity of the enzyme responsible for converting the 
pro-drug into an active agent (Gottesman, 2002). Drug resistance is one of the important 
factors responsible for low survival rate of pancreatic cancer patients. Numerous studies 
over the past two decades have suggested that pancreatic cancer is associated with various 
genetic alterations which contribute to its resistant characteristics (Almoguera, et al., 1988; 
Feldmann, et al., 2007; Hruban and Fukushima, 2007). Some of these mechanisms are listed in 
table 1: 
Mechanisms 5-Fluoruracil (Santi, McHenry et al. 1974; 
Wohlhueter, McIvor et al. 1980; Howell, 
Mansfield et al. 1981; Diasio and Harris 
1989; Lowe, Ruley et al. 1993; JL 1996; 
Ahnen, Feigl et al. 1998; Lenz, Hayashi et al. 
1998; Bunz, Hwang et al. 1999; Eisold, 
Linnebacher et al. 2004;  
Zhang, Yin et al. 2008) 
Gemcitabine (Bergman, 
Pinedo et al. 2002; 
Galmarini, Clarke et al. 
2002; Garcia-Manteiga, 
Molina-Arcas et al. 2003; 
Yokoi and Fidler 2004; 
Nakano,  
Tanno et al. 2007) 
MOA 
related 
Thymidylate synthetase Ribonucleotide reductase 
Transporters MRP 3 and 5 MDR1 
Molecular Akt, src Akt, NF κB, src 
Table 1. Suggested mechanisms for drug resistance in pancreatic cancer 
Some of the markers of gemcitabine resistance include decreased expression of dCK, 
increased levels of competing dCTP, low levels of hENT, and alteration of PI3K/Akt/NFκB 
pathway, FAK, and hypoxia (Almoguera, et al., 1988; Feldmann, et al., 2007; Hruban and 
Fukushima, 2007) 
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3.2 5FU resistance 
Resistance to 5FU induced cytotoxicity or cancer cells’ response to 5FU treatment is 
controlled/characterized by various factors (Kang and Saif, 2008; Zhang, et al., 2008), as 
discussed below. 
3.2.1 Thymidylate Synthase (TS)  
TS controls several aspects of a tumor’s response to 5FU therapy. Increase in the TS level can 
reduce the accumulation of activated metabolites of 5FU and hence reduce toxicity. Also, 
mutation of the enzyme can decrease 5FU’s affinity to TS. TS overexpression is considered 
as a major mechanism responsible for 5FU resistance. Decreased levels of reduced folate 
substrate, 5,10-methyltetrahydrofolate, also reduces 5FU response. 
3.2.2 Dihydropyrimidine dehydrogenase (DPDY) 
Increase in the activity of DPDY can increase the catabolism of 5FU leading to its 
inactivation. Other studies have shown that low-DPDY tumors are more responsive to 5FU 
treatment. 
3.2.3 Slow down of cell cycle 
This mechanism can prevent the incorporation of 5FU metabolites in the cells and provide 
the cells with sufficient time to correct the misincorporated nucleotides. 
3.2.4 Human Equilibrative Nucleoside Transporters (hENT) 
These transporters are important for delivery of 5FU from the extra-cellular space into cells. 
Levels of hENT1 has been correlated with pancreatic cancer cell sensitivity to 5FU response 
and few studies have suggested that hENT plays an important role in 5FU resistance. 
hENT1 mRNA levels are suggested to be a useful marker to predict 5FU sensitivity (Kang 
and Saif, 2008; Zhang, et al., 2008) 
3.2.5 Other factors causing 5FU resistance 
Mutated p53 
This tumor suppressor gene, which is mutated in 30-70 % of pancreatic cancer cases, can 
affect 5FU response in pancreatic cancer cases. Wild type p53 expression is required for 5FU- 
induced apoptosis and p53 status of tumor cells can determine the response to 5FU-based 
chemotherapy (Ahnen, et al., 1998; Bunz, et al., 1999; Lenz, et al., 1998; Lowe, et al., 1993). 
Another study found that transfection of pancreatic cancer cells with wild type p53 
synergistically enhances the cytotoxicity of 5FU both in vivo and in vitro. The same study 
also showed that pancreatic cancer cell line with wild type p53 status was more sensitive to 
5FU as compared to the p53 mutated line (Eisold, et al., 2004). 
Mutated EGFR-Ras-MAPK cascade 
This signaling pathway is important for growth, survival and proliferation of cells. The 
signaling cascade is found to be mutated at various levels in pancreatic cancer, leading to 
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over-activation of the pathway and hence increased growth and proliferation of the cancer 
cells (References). Protein expression of members of this pathway can modulate the 
cytotoxic effect of 5FU on pancreatic cancer cells. Blockade of EGFR increases the 
cytotoxicity of 5FU in both in vivo and in vitro conditions (Overholser, et al., 2000). 
Furthermore, activation of MAPK reduces the sensitivity of pancreatic cancer cells to 5FU 
treatment in vitro (Wey, et al., 2005). K-ras mutation is the hallmark of pancreatic cancer and 
occurs early during the development of pancreatic neoplasia. Ras-mutated pancreatic cells 
have shown to respond better to 5FU treatment as compared to their non-ras-transformed 
counterparts (Hiwasa, et al., 1996). 
4. Relationship of resistance to cellular processes 
The mechanisms involved in drug resistance in pancreatic cancer are different for different 
drugs. In a broad sense, drug resistance in pancreatic cancer can be linked to modulation of 
enzymes, receptors, DNA repair and other processes. These are discussed in depth in this 
section. For drugs to be effective, they should be transported successfully into the cells, 
reach their respective effective concentrations and should form their active forms before 
they are transported out of cells (Longley, et al., 2003; Plunkett, et al., 1995)  
4.1 Enzyme linked mechanisms 
The expression levels of the enzyme DCK determines the patient survival and the sensitivity 
of a tumor to gemcitabine (Hagmann, et al., 2010a; Plunkett, et al., 1995). HuR is a RNA-
binding protein that modulates the translation of DCK mRNA and multiple other proto-
oncogenic proteins in cancer cells (Williams, et al., 2010). Modulation of mRNA is dependent 
on stress conditions and includes the presence of therapeutic agents. Expression of HuR 
increases in pancreatic cancer cells treated with gemcitabine and an increased level of HuR 
in the cytoplasm is a marker of gemcitabine sensitivity (Costantino, et al., 2009). pp32 is a 
protein phosphatase and tumor suppressor gene that regulates the post- transcriptional 
activity of mRNA to which the HuR protein binds. Although the exact mechanism by which 
pp32 regulates HuR is yet to be unveiled, researchers have cited possible ways by which 
pp32 regulates the post-transcriptional changes of transcribed mRNA. The possibilities 
include: a) disrupting the interaction of HuR with mRNA in the nucleus, b) inhibiting 
translocation of the HuR-bound mRNA into cytosol and thereby inhibiting translation of 
oncogenic proteins, and other possible mechanisms (References). Overexpression of pp32 
can result in inhibition of dCK mRNA translation and hence poor gemcitabine efficacy 
(Williams, et al., 2010). 
Thymidylate synthetase (TS) controls a tumor’s response to 5FU therapy. Increase in the TS 
level can reduce the accumulation of activated metabolites of 5FU and hence reduce toxicity. 
Additionally, mutation of the enzyme can decrease its affinity to TS. TS overexpression is 
considered as a major mechanism responsible for 5FU resistance. Decreased levels of 
reduced folate substrate, 5,10-methyltetrahydrofolate, also reduces 5FU response (Zhang, et 
al., 2008). 
Increase in the activity of dihydropyrimidine dehydrogenase (DPDY) can increase the 
catabolism of 5FU leading to its inactivation. Few studies have shown that low-DPDY 
tumors are more responsive to 5FU treatment. 
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5FU resistance can result from induction of TS levels upon administration of 5FU which 
brings about the activation of autoregulatory feedback pathway where the TS protein 
regulates the translation of its mRNA. The salvage pathway involving the enzyme 
thymidine kinase, the biochemical reaction in which thymidylate is derived from thymidine 
could be one of the ways the cells acquire resistance to 5FU. (Zhang, et al., 2008) 
4.2 Receptor linked mechanisms 
4.2.1 Drug uptake 
Due to structural similarity to the nucleosides, a drug can enter the cells through uptake by 
the concentrative nucleoside transporters (CNT's) and equilibrative nucleoside transporters 
(ENT's). CNT1 and CNT3 have high affinity for gemcitabine whereas ENT1 and ENT2 have 
lower affinity for gemcitabine. Pancreatic tumor cells exhibit higher expression levels of 
ENT1 but low to negligible levels of CNT 3. This phenotype affects the transport of 
gemcitabine into the cancer cells and ultimately gemcitabine’s action on DNA and RNA 
synthesis. The expression levels of ENT1 and CNT3 provide an index of patient survival 
after gemcitabine treatment (Hagmann, et al., 2010b). 
In the case of 5FU, resistance was found to be imparted due to overexpression of ENT1. A 
study using 7 pancreatic cancer cell lines (AsPC1, BxPC3, MiaPaCa-2, PSN1, Panc1, PCI6, 
and KMP-4) reported an increased expression of ENT1 mRNA, which correlated with the 
IC50 of 5FU in the AsPC1 cell line, a cell line most resistant to 5FU among the cell lines tested 
(Tsujie, et al.; 2007). Thymidylate synthase (a target of 5FU) and dihydropyrimidine 
dehydrogenase (DPDY), which metabolizes 5FU, were not overexpressed with simultaneous 
overexpression of ENT1: this phenotype implies that the toxicity of 5FU was countered by 
increased uptake of nucleosides and nucleotide bases through the salvage pathway (Tsujie, 
et al., 2007). It is therefore widely accepted that ENT1 overexpression serves as a marker of 
5FU resistance (Huber-Ruano and Pastor-Anglada, 2009; Tsujie, et al., 2007). 
4.2.2 Drug efflux 
Drug efflux is one of the potential means by which cancer cells exhibit chemoresistance: it is 
mediated by a family of proteins, ATP binding cassette (ABC) proteins, which involve ATP 
utilization (Wu, et al., 2008). The human genome encodes 49 members of this protein family 
and about 15 proteins are implicated in cancer chemoresistance. These transporters have an 
intracellular nucleotide binding domain that hydrolyses ATP and results in conformational 
change in its structure leading to the transmembrane domain forming a channel-like structure 
through which the drug is effluxed to the extracellular space(Santisteban, 2010). P glycoprotein, 
multidrug resistance associated protein (MRP1) and breast cancer resistance protein (BCRP) 
constitute the universal drug efflux transporters (Santisteban, 2010; Wu, et al., 2008). 
The efflux of gemcitabine and its triphosphate metabolite is mediated by multidrug resistant 
protein 5 (MRP5), which is a member of the ATP binding cassette (ABC) family of proteins. 
Evidences in support of the role of MRP3, MRP4 and MRP5 in the efflux of etoposide, 5FU 
and gemcitabine suggest that these MRP's are directly linked with the resistance phenotype 
(Hagmann, et al., 2010a; Hagmann, et al., 2010b). Transcriptional regulation of MRP's by 
nuclear factor like 2 protein (Nrf2) is an important target to overcome resistance because 
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overexpression of Nrf2 is associated with increased resistance of cells towards 
chemotherapy-induced cell death (Hagmann, et al., 2010a). 
Evidences in support of overexpression of these transporters in cancer stem cells and failure 
of the classical concept of direct inhibition of transporters in resistant cells using the first 
generation inhibitors like verapamil and quinidine and second generation inhibitors like 
valspodar and biricodar have led researchers to focus on the pathways that may be involved 
(Santisteban, 2010). 
4.3 Role of hedgehog pathway in resistance 
Hedgehog signaling between the tumor cells and stromal cells brings about a desmoplastic 
reaction where the stromal fibroblasts secrete collagen in higher amounts and result in 
fibrosis of the surrounding stromal tissue. Hedgehog signaling also has a key role in 
promoting epithelial mesenchymal transition and the acquisition of mesenchymal 
phenotype is associated with over expression of ABC transporters in breast cancer and in 
pancreatic adenocarcinoma (Santisteban, 2010). Studies using KPC (Kras and p53 mutant) 
mice with PDAC (Pancreatic Ductal Adenocarcinoma) highlighted the role of hedgehog 
pathway in resistance aided by the desmoplastic reaction where the mean vascular density 
to the tumor tissue decreased and resulted in decreased delivery of gemcitabine to the 
tumor tissue (Olive, et al., 2009). Use of a pathway inhibitors like cyclopamine derivatives, 
that inhibit the protein smoothened, which is downstream of hedgehog signaling prevents 
transcriptional activation of target genes that bring about resistance by promoting 
overexpression of ABC transporters and by preventing desmoplasia (Olive, et al., 2009; 
Santisteban, 2010). 
4.4 Role of MAPK in resistance 
Three types of mitogen activated protein kinases (MAPK) have been identified in humans, 
including the extracellular signal regulated kinases (ERK), c-Jun N-terminal kinases and the 
p38 MAP kinases and all these act by serine/threonine phosphorylation of target proteins 
(Wagner and Nebreda, 2009). Interestingly, ERK pathway activation promotes survival while 
activation of JNK and p38 MAPK pathways induce apoptotic cell death as they are activated 
under stress conditions (Wagner and Nebreda, 2009; Zhao, et al., 2006a). Involvement of 
MAPKinase pathways in acquired chemoresistance has been studied by researchers but a 
clear idea of the mechanisms involved has yet to be established. ERK pathway which is 
downstream of EGFR signaling, promotes cell survival through its pro-survival signals which 
may be responsible for chemoresistance. Employing the SW 1990 cell line, Zhao et al 
demonstrated that ERK signaling regulates chemoresistance depending on the 
chemotherapeutic agent. Resistant cell lines exhibit a higher level of ERK activity as compared 
to sensitive cell lines and that inhibition of ERK pathway resulted in 5FU sensitivity but 
increased GEM resistance. 5FU acts by activating intrinsic apoptotic pathway whereas GEM 
induces cell death by activating extrinsic apoptotic pathway (Zhao, et al., 2006a). 
4.5 Role of PI3K/Akt pathway in resistance 
As opposed to earlier notions that drug resistance arises by increased drug metabolism or 
efflux or decreased transport of the drugs into the cells, Ng et al.(2000), using PK1 and PK8 
cell lines, demonstrated that the anti-apoptotic advantage of cells towards gemcitabine is 
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conferred not by the classical resistance mechanisms alone but also by the activation of 
PI3K/Akt pathway when the intracellular concentration of gemcitabine was found to be 
effective to affect DNA and cell cycle (Ng, et al., 2000). PI3K/Akt pathway activation stems 
from phosphorylation of receptor tyrosine kinases and the regulatory subunit of PI3K, the 
p85 interacts with the active tyrosine kinase domains for activation. Activation of PI3K 
results in phosphorylation of its substrates which includes phosphoinositides and protein 
kinase B (PKB), otherwise called Akt. Phosphorylation of Akt and its subsequent nuclear 
translocation results in transcriptional activation of genes that promote cell survival 
(Hennessy, et al., 2005; Ng, et al., 2000). Apart from this mechanism, the phosphorylated Akt 
is also shown to inactivate the pro-apoptotic protein BAD by phosphorylating it and thereby 
giving the anti-apoptotic advantage to the cells. In addition, the activation of PI3K can also 
occur by interaction of the catalytic subunit of PI3K (p110 subunit) with constitutively active 
membrane bound Ras (Ng, et al., 2000). 
4.6 Role of Zeb-1 in resistance 
Zeb1 is a transcriptional suppressor of E-cadherin which is involved in cell-cell adhesion 
and is the marker of epithelial cells. By doing so, it promotes epithelial-mesenchymal 
transition (EMT) upon which the cells metastasize and form secondary tumors (Wellner, et 
al., 2010). Epithelial mesenchymal transition is a process by which the tumor cells with 
epithelial lineage origin acquire the mesenchymal phenotype. This process gives them an 
advantage of migrating from the primary tumor site into the blood stream and  
develop secondary tumors at various sites depending on the availability of suitable 
microenvironment. The whole process is called metastasis which is dependent on EMT. 
During EMT, the epithelial cells lose epithelial cell surface markers, express mesenchymal 
markers and undergo cytoskeletal remodeling in which the cell polarity, a characteristic of 
the epithelial cells, is lost and the cells acquire an invasive phenotype. Downregulation of E-
cadherin and upregulation of mesenchymal markers vimentin, smooth muscle actin, 
gamma-actin, beta-filamin, talina and extracellular matrix components like fibronectin and 
collagen precursors are key features of EMT (Christiansen and Rajasekaran, 2006; Kalluri and 
Weinberg, 2009). 
Recent studies on the role of Zeb-1 by Arumugam et al. (2009) confirmed the role of Zeb-1 not 
only in promoting metastasis but also in drug resistance. This group found that the cancer 
cell lines which are sensitive to gemcitabine (L3.6pl, BxPC3, CFPAC, SU86.86) are more 
sensitive to 5FU and cisplatin as compared to the gemcitabine-resistant cancer cell lines 
(PANC-1, Hs766T, AsPC-1, MIAPaCa-2, MPanc96). When Zeb-1 activity was silenced using 
siRNA in PANC1, MIAPaCA-2 and Hs766T cell lines, there was increased apoptosis in these 
cell lines on treatment with gemcitabine, 5FU or cisplatin, separately. This finding suggests 
an important role for Zeb-1 in drug resistance. Erlotinib is an EGFR inhibitor that is used in 
combination with gemcitabine to treat pancreatic cancer. Resistance to EGFR inhibition is a 
hallmark of EMT which can be reverted by silencing the activity of Zeb-1, which in turn 
increases sensitivity of the cells to EGFR inhibition (Arumugam, et al., 2009). 
4.7 Role of NFκB in inducing gemcitabine resistance 
Nuclear factor kappa light chain enhancer of activated B-cells (NFκB) is a complex involved 
in important cellular processes like inflammation, apoptosis regulation and stress 
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adaptation. In the cell, it is present tightly bound to inhibitory proteins like IkBa and is 
released in response to stimuli that bring about activation of IkB kinase (IKK). The free 
cytosolic NFκB then translocates into the nucleus where it regulates gene expression. The 
role of NFκB in gemcitabine resistance has been demonstrated. Arlt et al. (2003), using 
gemcitabine resistant (BxPC3 and Capan1) and gemcitabine sensitive (T3M4 and PT45-P1) 
cell lines, found that the autocrine loops for generation of NFκB play an important role in 
gemcitabine resistance. Employing NFκB inhibitors (MG132 or sulfasalazine), they found 
basal NFκB levels confer resistance and the basal NFκB levels are not affected by the 
activated or inactive state of PI3K/Akt pathway (Arlt, et al., 2003). 
4.8 Role of notch signaling in chemoresistance 
Notch signaling is a developmental pathway which is implicated in organogenesis, 
development of nervous and vascular systems and hematopoietic stem cell generation in 
adults (Chiba, 2007). Notch signaling is important for self-renewal of stem cell and along with 
Wnt signaling, it prevents terminal differentiation of cells (Katoh, 2007). Overactivity of Notch 
signaling is observed in various hematopoietic and solid tumors leading to proliferation, and 
inhibition of differentiation and apoptosis. In pancreatic cancer cells, Notch signaling is 
implicated in drug resistance. Wang et al. found that components of Notch signaling pathway 
are upregulated in gemcitabine resistant pancreatic cancer cells and are associated with 
increase invasiveness (Bao, et al., 2011b; Wang, et al., 2009). Yao and Qian (2010) observed that 
inhibition of Notch3 by the siRNA approach increases gemcitabine-induced cytotoxicity in 
pancreatic cancer cell via affecting the PI3K/Akt pathway. The studies mentioned above 
strongly suggest that cancer stem cell signaling pathways could be attractive targets for 
increasing their sensitivity to chemotherapeutic agents (Bao, et al., 2011b). 
4.9 Miscellaneous other mechanisms 
A role of for the glycoprotein, mucin MUC4, in pancreatic cancer cell resistance to the first line 
chemotherapeutic agent, gemcitabine has recently emerged. Mucin MUC4 is overexpressed on 
the membrane of pancreatic cancer cells but not normal pancreatic cells (Santisteban, 2010). 
Studies on this glycoprotein’s involvement in gemcitabine resistance have revealed the 
interaction of this glycoprotein with the HER2 receptor and the subsequent activation of ERK 
pathway and phosphorylation of the pro-apoptotic protein BAD which inhibits apoptosis 
induced by gemcitabine (Ponnusamy, et al., 2008; Santisteban, 2010). 
5. Overall strategies to overcome resistance 
5.1 miRNA 
miRNA (miR) are 18-24 nucleotide-long RNA molecules which can regulate the translation 
of mature RNA into protein. They are synthesized as a 60-80 nucleotide-long, hairpin-
shaped RNA molecule which is transported to the cytoplasm where it undergoes processing 
to form 18-24 nucleotide-long double stranded RNA molecule. One of the strands then 
interacts with RNA-induced silenced complex (RISC) and targets RNA translation. Various 
miRNAs have been demonstrated to play a role in development and cancer progression. 
Dysregulation of miRNAs has also been observed in pancreatic cancer tissues and cell lines. 
Bloomston et al. (2007) found that the levels of miRNAs can be used to differentiate between 
www.intechopen.com
 Failure of Pancreatic Cancer Chemotherapy: Consequences of Drug Resistance Mechanisms 
 
153 
pancreatic tumor, chronic pancreatitis and benign pancreatic tissue. They also found that the 
expression of six miRNAs can predict the survival of the pancreatic cancer patients 
(Bloomston, et al., 2007). Zhang et al. (2009) profiled the levels of 95 miRNAs in pancreatic 
tumors, pancreatic cancer cell lines, pancreatic tissues and pancreatic ductal epithelial cells. 
They found that the expression of 8 miRNAs were significantly upregulated in pancreatic 
cancer tissues and cancer cell lines compared to the pancreatic tissues and pancreatic ductal 
cells (Zhang, et al., 2009). 
Deregulated miRNA levels could serve as attractive targets for treatment of pancreatic 
cancer. Moriyama et al. (2009) found that the level of miR21 is upregulated in pancreatic 
cancer cells and its inhibition decreases proliferation, invasion, chemoresistance and induces 
cell cycle arrest and apoptosis in pancreatic cancer cells. On the other hand, Banerjee et al., 
(2007) found that the expression of miRNAs can be modulated by natural compounds which 
reduce EMT and chemoresistance in pancreatic cancer cells. These studies strongly suggest 
that deregulated levels of miRNA in pancreatic cancer can be exploited as putative 
therapeutic targets for overcoming pancreatic cancer drug resistance. 
5.2 Stem cell signaling 
Some studies have suggested that a tumor comprises of heterogeneous populations of cells 
rather than just homogenous cell types. One subset is suggested to be distinct cells that have 
limited proliferative capacity but are responsible for initiation, progression and 
differentiation of cancer cells. Due to their ability to self-renew and differentiate like stem 
cells, these cells are termed as “cancer stem cells.” There have been attempts with some 
successes to isolate the cancer stem cells so that they can be employed to elucidate genotypic 
and phenotypic characteristics as well as develop effective therapies to target to them 
because of their ability to self-renew and their resistance to conventional chemo- and/or 
radiation therapies.  
Li et al. ( 2007) isolated pancreatic cancer cells which were highly tumorigenic and had the 
ability to self-renew based on their cell surface markers. These cells (CD44*CD24* ESA*) 
comprises of 0.2-0.8% of all pancreatic cancer cells and were able to produce differentiated 
progeny. Similarly, Herman et al. (2007) isolated pancreatic cancer stem cells which were 
CD133+.  
The cancer stem cells are known to be resistant to conventional chemo-radiation therapies. 
Michor et al. showed that a subpopulation of chronic myeloid leukemia stem cells were 
resistant to imatinib (Michor, et al., 2005). In glioblastoma, enrichment of CD133+ cells was 
observed after treatment with ionizing radiation. These cells activate DNA damage response 
upon irradiation and therefore are resistant to ionizing radiation (Bao, et al., 2006). Similarly, 
enrichment of cells with stem cell characteristics is observed on treatment of pancreatic 
cancer with radio- or chemotherapy (Hermann, et al., 2007; Li, et al., 2007). 
5.3 Natural compounds for reversing resistance 
Dietary habit of individuals has been correlated with development of pancreatic cancer. 
High cholesterol diet increases the risk of pancreatic cancer (Baghurst, et al., 1991; Ghadirian, 
et al., 1991; Howe, et al., 1992; Stolzenberg-Solomon, et al., 2002). Diet rich in fruits and 
vegetables is associated with reduced risk while intake of red meat is associated with 
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increased risk of developing pancreatic cancer (Boyle, et al., 1989; Inoue, et al., 2003; Ohba, et 
al., 1996; Tavani, et al., 2000).  
Various natural compounds have been tested for their anti-pancreatic cancer properties in 
laboratory settings. Kunnumakkara et al. (2001) showed that curcumin inhibits NFκB 
activation and increases the cytotoxicity of gemcitabine in vitro and in vivo. That study also 
found that curcumin decreases the microvascular density thereby decreasing angiogenesis 
(Kunnumakkara, et al., 2007). NFκB is involved in mediating resistance against gemcitabine 
and TRAIL, which may explain the increase in cytotoxicity. Curcumin also increased the 
accumulation of MRP5 substrate intracellularly in MRP5 positive cells; however, in the 
absence of MRP5, drug accumulation was not observed. Additionally, curcumin increased 
the cell’s sensitivity to 5FU (Li, et al., 2010). Furthermore, hydroethanolic extract of curcumin 
(Tumeric Force) was more effective than curcumin in this effect. 
Another group of natural compounds which are currently being investigated are 
isoflavones. One of the most well studied isoflavones, genistein has been tested extensively 
in pancreatic cancer. Various groups have shown that treatment with genistein controls 
proliferation, mitogenic signaling, invasion, migration and induces apoptosis in pancreatic 
cancer. Benerjee et al (2007) showed that genistein augments in vitro and in vivo efficacy of 
cisplatin in pancreatic cancer (Banerjee, et al., 2007). Previously, genistein was known to 
affect the activation of NFκB via the Akt pathway(El-Rayes, et al., 2006), which have been 
shown to be involved in pancreatic cancer drug resistance. Natural compounds (e.g., 
genistein, curcumin) have also been shown to inhibit the hedgehog and Notch signaling 
which provide the cancer cells with stem-cell like property of self-renewal and resistance 
(Slusarz, et al., 2010). A recent study noted upregulation of FOXM1, increased EMT, and 
cancer stem cell phenotype in pancreatic cancer (Bao, et al., 2011a). Treatment with natural 
compounds also reduced the levels of FOXM1 in pancreatic cancers. 
Apart from the above mentioned approaches and based on the literature cited in this 
chapter, there are some other strategies to overcome resistance including potential targets 
and areas for drug discovery like developing agents that regulate Nrf2 activity selectively in 
tumor cells, agents that inhibit interaction between mucin MUC4 and HER2, selective 
inhibition of hedge hog pathway in the tumor cells, selective inhibition of PI3K/Akt 
pathway in tumor cells, combination of anti-NFkB agents with gemcitabine and Zeb1 
silencing. Targeting sphingolipid metabolism is another approach to overcome resistance to 
gemcitabine (Guillermet-Guibert, et al., 2009). Recent renewed interests in the metabolic 
phenotypes of pancreatic and other cancers have raised possibilities of metabolic pathway(s) 
as drug targets for new anti-cancer drug discovery. 
6. Conclusions 
Although these strategies to overcome resistance to drugs are crucial for improving the 
outcome of chemotherapy, there is an urgent need to achieve early detection of pancreatic 
cancer. Finding novel biomarkers for detecting pancreatic cancer should be emphasized. 
Recent renewed interests in the metabolic phenotypes of pancreatic and other cancers have 
raised possibilities of metabolic pathway(s) as targets for strategies for developing agents for 
early tumor detection to addition to exploiting them as targets for new anti-cancer drug 
discovery. 
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